Welcome to our dedicated page for Global Technologies SEC filings (Ticker: GTLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Global Technologies, LTD filings document the reporting status, audit process, and public-company disclosures of an OTC operating company with subsidiaries in health and wellness and related services. Recent Form 8-K filings disclose Regulation FD and other-event updates about independent audit completion, PCAOB-registered auditor oversight, restatement of 2024 financial statements, amended quarterly reporting, and periodic-report status.
The filing record also includes Form 12b-25 notices for delayed quarterly reports, which provide required explanations for late Form 10-Q submissions. These filings frame GTLL’s formal disclosures around auditor engagement, financial-statement restatement, periodic-report timing, corporate updates, and Exchange Act reporting obligations.
Global Technologies, LTD outlined a restructuring-focused strategy combining new governance tools, a strategic partnership plan, and operating progress. The company signed a binding letter of intent with FORCARA, LLC to create an interim joint venture and revenue-sharing arrangement, including a $12,500 per month management fee and a 50/50 split of EBITDA or net operating profit. Any final acquisition or merger remains subject to due diligence, definitive agreements, and Board approval, with no assurance of completion.
The Board issued three shares of Series K Super Voting Preferred Stock to CEO H. Wyatt Flippen to support governance continuity and approved a new Series R Preferred Stock designation authorizing 250,000 shares for compensation, strategic transactions, and capital-structure planning. William “Bill” Norton joined the Board with an amended executive and board agreement at the parent level.
In its Form 10-Q for the nine months ended March 31, 2026, the company reported $642,822 in revenue and $38,178 in cash and cash equivalents. Primecare Supply, LLC generated approximately $404,625 in gross product sales and $71,581 in net revenue, reflecting a net revenue recognition model. Since October 2025, GTLL has opened relationships with more than 150 cash-pay clinics and over 20 other small businesses while developing advisory services and AI-enabled tools to deepen client relationships despite ongoing working capital constraints.
Global Technologies, Ltd. reports a net loss for the three and nine months ended March 31, 2026 while continuing to operate with a stockholders’ deficiency and going concern uncertainty. For the nine-month period, revenue was $642,822, with shared revenue of $317,315, resulting in net revenue of $325,507 compared with $666,115 a year earlier.
The company recorded a net loss of $170,524 for the nine months, versus net income of $24,055 in the prior-year period, driven by operating expenses of $755,260. A $282,000 non-cash gain on derivative liability partially offset these costs. Cash used in operating activities was $259,830, leaving cash of $38,178 as of March 31, 2026.
Total assets were $42,399 against total liabilities of $1,136,202, resulting in stockholders’ deficiency of $1,093,803 and an accumulated deficit of $167,726,161. The capital structure includes variable-price convertible notes with a related derivative liability of $498,000 and new Series P Preferred Stock issuances totaling $230,000 of proceeds. Management discloses substantial doubt about the company’s ability to continue as a going concern and outlines plans to seek additional financing and partnerships while transitioning its business toward technology-enabled healthcare procurement and advisory services.
Global Technologies, LTD filed a current report describing a major clean-up of its financial reporting. The company completed a comprehensive two-year independent audit, including an audit and restatement of its 2024 financial statements, under a PCAOB-registered auditing firm.
It also filed Quarterly Reports for the periods ended September 30, 2025 and December 31, 2025, including an amended Form 10-Q/A reviewed by the auditor. Global Technologies confirms it is now current with all required SEC periodic filings through the quarter ended December 31, 2025, aiming to strengthen transparency, internal controls, and investor confidence.
Global Technologies, Ltd. filed an amended quarterly report for the six months ended December 31, 2025 after review by its independent auditor. The amendment mainly refines disclosures and classifications in Notes K and L and does not change previously reported totals. The company remains very small, with cash of $41,408, total assets of $45,629, current liabilities of $977,469, and a stockholders’ deficit of $931,840. Net revenue was $136,347 for the quarter and $233,275 year-to-date, with a quarterly net loss of $144,760 but modest six‑month net income of $21,439 helped by a $282,000 gain on derivative liability. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing a cumulative deficit of $167,534,198, negative operating cash flow of $226,600, and dependence on new funding, including deeply discounted convertible notes and preferred stock issuances.
Global Technologies, Ltd. reports very limited improvement in its financial position for the six months ended December 31, 2025. Net revenue fell to $233,275 from $612,124 a year earlier, and operating loss was $245,187. A non‑cash gain of $282,000 from revaluing derivative liabilities turned results into a small net income of $21,439.
Liquidity remains strained: cash was only $41,408, total assets were $45,629, and current liabilities were $977,469, leaving stockholders’ deficiency of $931,840. The company discloses substantial doubt about its ability to continue as a going concern and plans to seek additional funding through partnerships, debt and equity issuances.
Operations are shifting from the now‑idle 10 Fold Services unit toward Primecare Supply, a 503B pharmaceutical procurement platform, and the newly formed GTLL Advisory. A prior acquisition of GOe3, LLC was unwound after milestones were not met, allowing management to refocus on healthcare and technology‑enabled services.
Global Technologies, Ltd reported results for the quarter ended September 30, 2025, showing a small profit driven by a non-cash derivative gain but weak underlying revenue. Net revenue was $96,928, down sharply from $477,542 a year earlier, with one customer providing 100% of sales and two pharmaceutical suppliers supporting operations. Operating expenses were $205,142, producing an operating loss of $108,214, which was offset by a $282,000 gain from revaluing derivative liabilities tied to convertible notes, resulting in net income of $166,199.
Cash increased to $152,977 from $68,108, mainly from a $200,000 private placement of new Series P Preferred Stock. Total liabilities were $944,278 and stockholders’ deficit was $787,080, including an accumulated deficit of $167.4 million. The company highlights substantial doubt about its ability to continue as a going concern and plans to seek additional financing. Strategy is now focused on health-tech subsidiaries Primecare Supply and GTLL Advisory, while legacy ventures like GOe3 have been unwound.
Global Technologies, Ltd. reports on a year of restructuring around health-tech and advisory services while facing severe financial strain. The company now centers on Primecare Supply, a 503B pharmaceutical procurement business using its Sinq Ops platform, and GTLL Advisory, a consulting unit expected to begin generating revenue in fiscal 2026. A prior acquisition of EV-charging business GOe3 was unwound, and Global wrote off its entire investment and goodwill as of June 30, 2025. As of that date, the company had an accumulated deficit of $167,555,637 and a stockholders’ deficiency of $1,153,279, with no cash and no current income to cover operating expenses. Auditors included an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern, and management estimates it must raise about $500,000 to fund operations through June 30, 2026. Internal control over financial reporting was deemed ineffective due to material weaknesses, while the microcap stock remains thinly traded, highly dilutive with 14,688,440,097 Class A shares outstanding, and subject to penny stock rules.